AHA Scientific Sessions 2026 AbstractNov 9, 2026, 00:54 GMT

Orforglipron increased metabolic syndrome resolution in trials

At 36 milligrams, resolution after 72 weeks reached 62.8% versus 35.5% with placebo in ATTAIN-1 and 52.8% versus 15.1% in ATTAIN-2 among participants with metabolic syndrome at baseline.

Paper by Naveed Sattar, Alice Cheng, Elif Ekinci, +4Donna Mojdami · Sch of Cardiovascular and Metabolic Health · Eli Lilly and Company

Our read

Interventions

Studied:: Randomized trial in adults with obesity or overweight, 72 weeks, against placebo (Placebo-controlled, dose-response)
What changed:: At 36 milligrams, metabolic syndrome resolution was higher: 62.8% versus 35.5% with placebo in ATTAIN-1 and 52.8% versus 15.1% in ATTAIN-2
The catch:: The abstract did not report adverse events or whether participants had fewer cardiovascular events
In the record:: The 30th paper on orforglipron with results in people; 77 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Paper

Adults with obesity or overweight, with or without type 2 diabetes, received orforglipron or placebo for 72 weeks in two randomized trials. This post-hoc analysis examined metabolic syndrome, defined as at least three abnormalities involving waist size, blood pressure, blood sugar or blood fats. Capsule doses were 6, 12 and 36 milligrams.

Among participants with the syndrome at baseline, resolution rates at 36 milligrams were 62.8% versus 35.5% with placebo in ATTAIN-1, which enrolled adults with obesity or overweight with weight-related conditions. Those groups included 310 and 413 affected participants at baseline, respectively. In ATTAIN-2, which enrolled adults with type 2 diabetes, rates were 52.8% versus 15.1%; those groups included 278 and 554 affected participants at baseline. All three doses increased the odds of resolution compared with placebo, with a dose-related trend.

Why it matters

Metabolic syndrome’s links to cardiovascular disease and type 2 diabetes make it relevant to healthy aging. The authors suggested that orforglipron may offer benefits for heart and metabolic health beyond weight reduction alone.

Caveats

The findings came from a post-hoc analysis reported in a conference abstract. The abstract did not report adverse events or whether participants had fewer cardiovascular events.